STOCK TITAN

Acrivon Therapeutics Inc - ACRV STOCK NEWS

Welcome to our dedicated news page for Acrivon Therapeutics (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acrivon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acrivon Therapeutics's position in the market.

Rhea-AI Summary
Acrivon Therapeutics reports initial positive clinical data for ACR-368 and pipeline program progress at a corporate R&D event. The Phase 2b clinical data showed a 50% confirmed overall response rate with ACR-368 in OncoSignature-positive gynecological cancers. The AP3 patient selection platform was validated, and the IND timeline for ACR-2316 was accelerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, a clinical stage biopharmaceutical company, will host a virtual corporate R&D event to showcase progress on its precision oncology medicines, including ACR-368 OncoSignature and ACR-2316. The event will feature presentations on the AP3-driven pipeline, clinical data on ACR-368, preclinical updates on ACR-2316, and a demonstration of the AP3 Interactome tool.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.19%
Tags
conferences clinical trial
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclinical studies. AP3 profiling identified ULDG as a sensitizer for resistant ovarian cancer cells to ACR-368, a CHK1/2 inhibitor. Acrivon's precision proteomics-based approach in drug discovery and development was highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
none
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced a securities purchase agreement to issue 8,235,000 shares of common stock and pre-funded warrants, expecting gross proceeds of $130 million. The financing, led by new investors, will support the advancement of their lead clinical asset, ACR-368, and other pipeline programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.77%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighting progress in clinical trials for ACR-368 and ACR-2316. The company remains on track to present more mature clinical data in 2024 and has upcoming milestones for 2025. Recent highlights include advancements in IND-enabling studies for ACR-2316 and presentations at the AACR Annual Meeting. Financially, the company reported a net loss of $19.3 million for Q4 2023 and $60.4 million for the full year, with increased R&D and administrative expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announces the presentation of data at the AACR Annual Meeting for their novel dual WEE1 and PKMYT1 inhibitor, ACR-2316, developed using AP3. The company's CEO highlights the platform's ability to overcome drug resistance and present a rational combination treatment for their lead asset, ACR-368.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the appointment of Dr. Santhosh Palani, a seasoned healthcare investor and former drug developer, to its board of directors. Dr. Palani's expertise in biotechnology investments and drug development will enhance Acrivon's precision medicine platform, AP3, which aims to match oncology medicines to patients based on proteomics. His background at PFM Health Sciences and NEA brings valuable experience to Acrivon's innovative approach in oncology and potential expansion into other therapeutic areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.4%
Tags
management
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced its participation in a panel discussion at the TD Cowen 44th Annual Health Care Conference. The company is focused on developing precision oncology medicines using its proprietary platform, AP3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.07%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. Dr. Magovčević-Liebisch brings over 25 years of experience in global business, R&D operations, partnering activities, commercialization, and regulatory, legal, and IP strategies. She has held pivotal roles at Vigil Neuroscience, Inc., Ipsen, Teva Pharmaceutical Industries Ltd., and Dyax. Her expertise will benefit Acrivon as they advance their pipeline of novel compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
management
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is developing precision oncology medicines using its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The company's president and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on February 13, 2024, at 2:40 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
Acrivon Therapeutics Inc

Nasdaq:ACRV

ACRV Rankings

ACRV Stock Data

292.36M
3.98M
17.57%
69.76%
2.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Watertown

About ACRV

acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities